Obeso J - Search Results

1

Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update.

Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, Obeso J, Bezard E, Fernagut PO. Voon V, et al. Among authors: obeso j. Lancet Neurol. 2017 Mar;16(3):238-250. doi: 10.1016/S1474-4422(17)30004-2. Epub 2017 Feb 15. Lancet Neurol. 2017. PMID: 28229895 Review.

2

Motor complications associated with chronic levodopa therapy in Parkinson's disease.

Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G, Rodriguez ME, Martinez-Lage JM. Obeso JA, et al. Neurology. 1989 Nov;39(11 Suppl 2):11-9. Neurology. 1989. PMID: 2685647 Review.

3

Impact of deep brain stimulation on upper limb akinesia in Parkinson's disease.

Brown RG, Dowsey PL, Brown P, Jahanshahi M, Pollak P, Benabid AL, Rodriguez-Oroz MC, Obeso J, Rothwell JC. Brown RG, et al. Among authors: obeso j. Ann Neurol. 1999 Apr;45(4):473-88. doi: 10.1002/1531-8249(199904)45:4<473::aid-ana9>3.0.co;2-v. Ann Neurol. 1999. PMID: 10211472

4

The impact of deep brain stimulation on executive function in Parkinson's disease.

Jahanshahi M, Ardouin CM, Brown RG, Rothwell JC, Obeso J, Albanese A, Rodriguez-Oroz MC, Moro E, Benabid AL, Pollak P, Limousin-Dowsey P. Jahanshahi M, et al. Among authors: obeso j. Brain. 2000 Jun;123 ( Pt 6):1142-54. doi: 10.1093/brain/123.6.1142. Brain. 2000. PMID: 10825353

5

The basal ganglia and disorders of movement: pathophysiological mechanisms.

Obeso JA, Rodríguez-Oroz MC, Rodríguez M, Arbizu J, Giménez-Amaya JM. Obeso JA, et al. News Physiol Sci. 2002 Apr;17:51-5. doi: 10.1152/nips.01363.2001. News Physiol Sci. 2002. PMID: 11909992 Review.

6

How does Parkinson's disease begin? The role of compensatory mechanisms.

Obeso JA, Rodriguez-Oroz MC, Lanciego JL, Rodriguez Diaz M. Obeso JA, et al. Trends Neurosci. 2004 Mar;27(3):125-7; author reply 127-8. doi: 10.1016/j.tins.2003.12.006. Trends Neurosci. 2004. PMID: 15036875 Free article. No abstract available.

7

Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.

Lang AE, Obeso JA. Lang AE, et al. Lancet Neurol. 2004 May;3(5):309-16. doi: 10.1016/S1474-4422(04)00740-9. Lancet Neurol. 2004. PMID: 15099546 Review.

8

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

Schapira AH, Obeso J. Schapira AH, et al. Among authors: obeso j. Ann Neurol. 2006 Mar;59(3):559-62. doi: 10.1002/ana.20789. Ann Neurol. 2006. PMID: 16489611 Review. No abstract available.

9

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.

Olanow CW, Obeso JA, Stocchi F. Olanow CW, et al. Lancet Neurol. 2006 Aug;5(8):677-87. doi: 10.1016/S1474-4422(06)70521-X. Lancet Neurol. 2006. PMID: 16857573 Review.

10

The globus pallidus pars externa and Parkinson's disease. Ready for prime time?

Obeso JA, Rodriguez-Oroz MC, Javier Blesa F, Guridi J. Obeso JA, et al. Exp Neurol. 2006 Nov;202(1):1-7. doi: 10.1016/j.expneurol.2006.07.004. Epub 2006 Aug 22. Exp Neurol. 2006. PMID: 16920102 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

558 results

Search Page

Filters